NanoViricides unveils new data showing lead drug asset’s strong activity against RSV
NanoViricides (NYSE-A:NNVC) has released new data which shows the strength of the antiviral activity of its lead drug asset NV-387…
1,372$
-1,20%
Echtzeit-Aktienkurs NanoViricides
Bid:
Ask:
Nachrichten zur NanoViricides Aktie
NanoViricides CEO discusses NV-387’s broad-spectrum antiviral potential
NanoViricides (NYSE-A:NNVC) has released a slew of new data supporting the safety and ultra-broad antiviral activity of its investigational therapeutic...…
NanoViricides to showcase lead drug asset’s progress at global conference
NanoViricides (NYSE-A:NNVC) announced that members of its leadership team will be attending the EF Hutton Annual Global Conference being held…
NanoViricides to showcase lead drug asset’s progress at EF Hutton Annual Global Conference
NanoViricides (NYSE-A:NNVC) announced that members of its leadership team will be attending the EF Hutton Annual Global Conference being held…
NanoViricides says lead asset shows antiviral activity against Smallpox and Mpox
NanoViricides (NYSE-A:NNVC) told investors that the ultra-broad antiviral activity spectrum of its lead drug asset NV-387 includes activity against the...…
NanoViricides drug asset shows ‘superior antiviral effects’ against Influenza A
NanoViricides (NYSE-A:NNVC) announced that its lead drug asset NV-387 has shown ultra-broad antiviral activity, including against Influenza A viruses. The...…
NanoViricides completes Phase 1 trial for respiratory viral infection candidate
NanoViricides (NYSE-A:NNVC) announced that a Phase 1 trial of its investigational therapeutic NV-387 has been completed. The company, a leader…
NanoViricides completes Phase 1 trial of lead asset NV-387
NanoViricides (NYSE-A:NNVC) announced that a Phase 1 trial of its investigational therapeutic NV-387 has been completed. The company, a leader…